Salud financiera de hoja de balance de Innate Pharma

Salud financiera controles de criterios 4/6

Innate Pharma tiene un patrimonio de los accionistas total de €51.9M y una deuda total de €39.1M, lo que sitúa su ratio deuda-patrimonio en 75.3%. Sus activos y pasivos totales son €184.2M y €132.3M respectivamente.

Información clave

75.3%

Ratio deuda-patrimonio

€39.06m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	€92.46m
Patrimonio	€51.90m
Total pasivo	€132.29m
Activos totales	€184.19m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (€148.0M) de IPHA superan a sus pasivos a corto plazo (€39.6M).

Pasivo a largo plazo: Los activos a corto plazo de IPHA (€148.0M) superan a sus pasivos a largo plazo (€92.7M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: IPHA tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de IPHA ha crecido de 1.5% a 75.3% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: IPHA tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si IPHA tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.

Salud financiera de hoja de balance de Innate Pharma

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma: Worth A Deeper Look

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

Innate Pharma GAAP EPS of €0.08, revenue of €45.59M

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Innate stock rises as Sanofi progress on 2nd cancer drug compound, pay €3M

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial

Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort

Innate Pharma: Leading The NK Cell Immunotherapy Space

Innate Pharma SA Announces Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia

Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides

Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting

Innate Pharma S.A. Announces New Lacutamab Data from Tellomak Trial in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma

Innate Pharma S.A. Advances Lacutamab Clinical Development Program

Innate Pharma: Attractive Price, But Comes With Uncertainty

Innate Pharma files $200M equity shelf

Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for Development

Rosen Law Firm Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action

Innate Pharma gives back US, EU Lumoxiti rights to AZN

Innate Pharma S.A., Annual General Meeting, May 28, 2021

Innate Pharma reports 9M results

Innate Pharma Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Innate Pharma S.A. Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

EMA grants PRIME tag to Innate Pharma's lacutamab for T-cell lymphoma

Innate Pharma Launches HopeConnectLearn: A New Online Resource for Hairy Cell Leukemia Patients

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera